Enveric Biosciences, a biotechnology company focused on developing novel neuroplastogens for neuropsychiatric disorders, has significantly expanded its patent protection. Five new US patents have been issued, and three more applications have been allowed by the United States Patent and Trademark Office, bolstering the intellectual property surrounding the company’s EVM301 portfolio. This portfolio comprises a wide array of tryptamine derivative molecules, including carboxylated, aminated, prenylated, glycosylated, nitrilated, and halogenated variations, as well as combinations of these functional motifs. These additions bring the total number of issued US patents protecting the EVM301 portfolio and its associated drug candidate library to nine.
This expanded patent protection enhances the potential value of Enveric’s drug candidate library. The company’s proprietary Psybrary™ contains over 1,000 tryptamine derivative molecules, incorporating receptor engagement and functional data to link molecular structure with biological activity. This broader portfolio with robust intellectual property protection creates more value-capture opportunities for Enveric. The portfolio not only increases the number and types of compounds available for development but also expands the range of potential therapeutic indications.
Furthermore, Enveric’s drug discovery platform has identified molecules exhibiting a preference for 5-HT2C receptors. These molecules, also protected by issued patent claims, hold promise as potential antiepileptic and anti-obesity drug candidates. They demonstrate enhanced binding preference for the 5-HT2C receptor compared to other serotonergic, dopaminergic, and adrenergic receptor targets.
The lead candidate from the EVM301 series, EB-003, is currently in preclinical development. This compound is being investigated for major undertreated mental health conditions, including treatment-resistant depression and anxiety, with plans to file an Investigational New Drug (IND) application in 2025. Preclinical data indicates a favorable safety profile for EB-003. Receptor engagement data suggests EB-003 can promote neuroplasticity without inducing hallucinations, a significant safety advantage over existing treatments. This characteristic is crucial for broader patient access, as hallucinations are a major concern limiting the use of some current therapies. Enveric, headquartered in Naples, FL, also maintains offices in Cambridge, MA, and Calgary, AB, Canada. The company’s focus is developing novel small-molecule therapeutics for depression, anxiety, and addiction disorders, leveraging its Psybrary™ platform to create new chemical entities for specific mental health indications.
Source link: http://www.businesswire.com/news/home/20241104428250/en/Enveric-Biosciences-Announces-Broad-Range-of-Patent-Issuances
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
